Elizabeth Marrett|Larry Radican|Michael J. Davies|Qiaoyi Zhang
Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study
MSD (United States)|MSD (United States)|MSD (United States)|MSD (United States)
oral antihyperglycemic agents may increase risk hypoglycemia thereby reduce patient quality life objective assess impact severity frequency selfreported hypoglycemia healthrelated quality life hrqol among patients type 2 diabetes treated oral antihyperglycemic agentsa followup survey conducted participants selfreported type 2 diabetes treated oral antihyperglycemic agents us national health wellness survey 2007 data collected severity frequency hypoglycemic episodes 6 months prior survey severity defined mild interruption activities moderate interruption activities severe needed assistance others severe needed medical attention hrqol assessed using euroqol5d questionnaire eq5d us weighted summary score utility worry subscale hypoglycemia fear survey hfs participants completed survey n 1984 mean age 58 years 57 male 72 reported hba1c 70 50 reported treatment sulfonylureacontaining regimen hypoglycemic episodes reported 63 patients 46 mild 37 moderate 13 severe 4 severe patients reporting hypoglycemia mean utility score significantly lower 078 versus 086 p 00001 mean hfs score significantly higher 175 versus 62 p 00001 compared patients reporting hypoglycemia differences mean scores without hypoglycemia increased level severity mild moderate severe severe utility 003 009 018 023 hfs 61 139 201 256 respectively adjusting age gender weight gain hba1c microvascular complications selected cardiovascular conditions utility decrement 0045 level severity 0009 0055 0131 0208 hfs increase 96 severity 53 124 176 232 hrqol decreased greater frequency hypoglycemic episodesselfreported hypoglycemia independently associated lower hrqol magnitude reduction increases severity frequency episodes patients type 2 diabetes treated oral antihyperglycemic agents